secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2023-08-16T23:59:59+00:00
Accession:  0000950170-23-042895
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences sells azer-cel rights to Imugene for up to $227M; cash runway extended to Q3 2025
--------------------------------------------------------------------------------

- Upfront consideration of $21M ($8M cash + $13M convertible notes); $8M milestone upon Phase 1b completion.
- Eligible for up to $198M in additional milestones for azer-cel plus double-digit royalties on net sales.
- Imugene gains global cancer rights to azer-cel and Precision's CAR T manufacturing infrastructure.
- Precision expects to reduce annual operating spend by ~$20M, extending cash runway through Q3 2025.
- Precision pivots exclusively to in vivo gene editing with ARCUS; retains non-oncology azer-cel rights.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/0000950170-23-042895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000095017023042895/dtil-20230815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-042895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer